norethindrone / Generic mfg. - LARVOL DELTA

Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial. (PubMed, Int J Womens Health) - "Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while potentially minimizing hypoestrogenic effects. Analgesic-free status improved in the placebo group after relugolix-CT initiation. In this post hoc analysis, women receiving relugolix-CT for up to 104 weeks had rapid dysmenorrhea improvement with amenorrhea and reduced analgesic use, with longer treatment associated with further NMPP reduction."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Norethisterone-Associated Decidual Cast Expulsion Mimicking an Acute Gynecologic Emergency: A Case Report. (PubMed, Clin Case Rep) - "It should be suspected in patients with severe colicky pain followed by sudden relief after tissue expulsion, especially with progestin use such as norethisterone. Accurate diagnosis and histopathology prevent unnecessary surgery."

Journal • Pain • Women's Health

BLOOM: Brain and Blood Vessel Health Following Endometriosis Treatment in People With Endometriosis (clinicaltrials.gov) - P4 | N=45 | Not yet recruiting | Sponsor: Colorado State University

New P4 trial • Endometriosis • Gynecology • Women's Health

Hidden in the History: A Case of Drug-Induced Liver Injury in a Medically Complex Patient (ACG 2026) - "The patient was admitted three months later for Amiodarone induced lung toxicity which was treated with a short course of prednisone and discontinuation of Amiodarone...At this time, she had a dental appointment and was given 2 grams of Amoxicillin... Our patient had numerous risk factors to develop elevated LE including DILI from Amiodarone, norethindrone or antibiotic use, congestive hepatopathy and ischemic hepatopathy...The typical timeline demonstrated with this type of DILI resembles that of our patientâs; a rapid rise in LE in a hepatocellular pattern upon initiation followed by rapid improvement of LE upon discontinuation. This case demonstrates the importance of thorough history taking when diagnosing DILI in medically complex patients."

Clinical • Autoimmune Hepatitis • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Women's Health

Differential Risk of GERD and Barrett's Esophagus Among Postmenopausal Women Receiving Estrogen-Only Versus Combined Hormone Therapy (ACG 2026) - "ET included estradiol or conjugated estrogens without progesterone; CHRT included estradiol with medroxyprogesterone, norethindrone, or progesterone... Before matching, 755,652 women received ET and 195,561 received CHRT. After matching, each cohort included 193,669 women, with standardized mean differences < 0.025 for most covariates. At 1 year, ET was associated with higher incident GERD diagnosis than CHRT (2.9% vs 2.2%; RR 1.29, 95% CI 1.24â1.35; HR 1.25; p< 0.001), GERD with esophagitis (RR 1.29, 95% CI 1.15â1.46; p< 0.001), incident Barrettâs esophagus diagnosis (RR 1.40, 95% CI 1.09â1.79; p=0.007), and anti-reflux surgery (RR 1.86, 95% CI 1.17â2.94; p=0.007)."

Clinical • Barrett Esophagus • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Acute Antral Mucosal Injury After Norethisterone Initiation in a Patient With a Long-Standing Intragastric Balloon (ACG 2026) - "She denied non-steroidal anti-inflammatory drug (NSAID), aspirin, herbal, alcohol, or tobacco use for 30 days prior...Norethisterone was stopped and omeprazole increased to 40 mg twice daily, with clinical resolution within 72 hours...Direct human evidence that norethisterone delays gastric emptying is absent, cycle-phase studies have not shown a consistent progesterone effect on emptying, and animal data are mixed and species-dependent...Figure: Higher-magnification view of the ulcer margin demonstrating heaped, irregular edges with surrounding inflamed mucosa. Biopsies showed acute inflammation without Helicobacter pylori, dysplasia, or malignancy."

Clinical • Addiction (Opioid and Alcohol) • Genetic Disorders • Infectious Disease • Obesity

The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta-analysis. (PubMed, Epileptic Disord) - "Current recommendations may underestimate ASM effects on exposure to COC components, especially those in newer COCs. Greater caution is recommended with low-dose topiramate. For individuals treated with weak COC inducers without additional contraceptive means, COCs containing levonorgestrel or norethindrone might be preferable given their lower vulnerability to induction."

Journal • Retrospective data • CNS Disorders • Epilepsy

Once-daily oral Gonadotropin-Releasing Hormone (GnRH) antagonists in the treatment of uterine fibroids: from evidence to clinical practice. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Among these agents, two once-daily oral GnRHa are approved for uterine fibroids: relugolix combination therapy (CT) (Ryeqo in the EU, Myfembree in the US), taken as a single tablet daily with add-back incorporated (relugolix 40 mg + estradiol 1 mg + norethindrone acetate 0.5 mg); and linzagolix, administered as 100 mg daily (partial suppression) or 200 mg daily (full suppression) (Yselty in the EU/UK), without or with add-back (an additional tablet with 1 mg estradiol + 0.5 mg norethindrone acetate). Linzagolix 200 mg is a suitable option for short-term preoperative fibroid reduction. Their distinct pharmacological profiles and dosing strategies may support different therapeutic objectives, including long-term symptom control and short-term preoperative management."

Journal • Review • Gynecology • Hematological Disorders • Solid Tumor • Uterine Leiomyoma • Women's Health

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - P3 | N=2753 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Dec 2033 ➔ Dec 2038

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4

Risk of ischemic and hemorrhagic stroke in users of progestogen-only contraceptives: A Danish registry study. (PubMed, Contraception) - "POCs-including POPs, implants, injections, and LNG-IUDs-were not associated with an increased risk of either IS or ICH and support their use as appropriate alternatives to CHCs with ethinylestradiol for women in whom stroke risk is an important clinical consideration."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke • Long-acting Reversible Contraceptives

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Nov 2026 ➔ Nov 2031

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Distinct immunomodulatory effects of synthetic progestins compared with natural progesterone in human immune cells. (PubMed, Immunohorizons) - "Only P4 induced immunoregulatory cytokine IL-10, whereas all progestins, except first-generation norethindrone, induced markedly higher IL-6 production compared with media control. In contrast, P4 selectively suppressed Th1 differentiation and promoted Th2 lineage commitment, whereas synthetic progestins failed to reproduce these immunoregulatory effects. Together, these findings demonstrate that synthetic progestins differentially regulate innate and adaptive immune responses compared with P4 and promote proinflammatory responses that may influence immune homeostasis."

Clinical • Journal • Immunology • Inflammation • CD14 • IL10 • IL6

Norethindrone Reduced Prolonged Bleeding Related to Etonogestrel Implant. (PubMed, Am Fam Physician) - No abstract available

Journal

Pedi-EVOLVE: Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Massachusetts General Hospital | Initiation date: May 2026 ➔ Aug 2026

Trial initiation date • Endocrine Disorders • Pediatrics

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P4 | N=12 | Recruiting | Sponsor: Rigel Pharmaceuticals

New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Case Series: Real-Life Experience with Vitex agnus-castus extract Ze 440 Medication in Adolescents. (PubMed, Complement Med Res) - "Ze 440 appears to be a practical, well-tolerated, non-hormonal option for managing menstrual disorders in adolescents. It supports the natural menstrual cycle without hormonal suppression. Regular clinical follow-up is recommended to optimize treatment outcomes and adjust therapy as needed."

Journal • Women's Health

Risk of venous thromboembolism with drospirenone only vs norethindrone only contraception in routine clinical care (ISTH 2026) - "The overall low event rate in both arms provides reassurance about the absolute VTE risk with drospirenone use in clinical practice. Table or Figure Upload (1) Population characteristics Page 2 Table or Figure Upload (2) Cumulative incidence of VTE in the full study cohort stratified by exposure Page 3 DOI*10.1016/j.rpth.2026.103833"

Clinical • Cardiovascular • Venous Thromboembolism

Contraceptive Progestogens and Incident Meningioma. (PubMed, JAMA Netw Open) - "For combined oral contraceptives, the estimated odds ratios (ORs) for the association between use of progestogens and meningioma were 1.61 (95% CI, 1.00-2.59) with cyproterone, 1.66 (95% CI, 1.31-2.10) with desogestrel, 1.58 (95% CI, 1.05-2.37) with drospirenone, 1.44 (95% CI, 1.17-1.77) with gestodene, 1.40 (95% CI, 1.12-1.76) with levonorgestrel, 1.38 (95% CI, 0.77-2.47) with norethisterone, and 1.04 (95% CI, 0.70-1.54) with norgestimate. In this case-control study conducted using data from the entire Danish population, recent use of the contraceptive progestogens cyproterone, desogestrel, drospirenone, gestodene, levonorgestrel, injectable medroxyprogesterone, and high-dose IUD was associated with increased risk of meningioma. These findings are considered relevant information for the treated women and the prescribing physicians."

Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Early Onset of Cerebral Venous Sinus Thrombosis in a 27-Year-Old Woman Receiving Norethisterone: A Rare Case Report. (PubMed, Case Rep Neurol) - "Management included therapeutic enoxaparin, levetiracetam prophylaxis, and levothyroxine discontinuation. The patient demonstrated rapid clinical improvement within 24 h, with near-complete radiographic resolution at 1-month follow-up after transitioning to apixaban. Norethisterone may precipitate early-onset CVST in patients with multiple prothrombotic risk factors, warranting cautious use and careful clinical evaluation."

Journal • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pain • Polyendocrine Metabolic Ovarian Syndrome • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Extreme Hypertriglyceridemia >10,000 mg/dL With Mild Clinical Presentation: A Case Report (ENDO 2026) - "History revealed multiple contributing factors, including discontinuation of insulin glargine one month prior and metformin one week prior, along with cessation of atorvastatin 20 mg daily six months earlier due to persistent myalgias attributed to fibromyalgia. She was also receiving tirzepatide, with recent exposure to antipsychotic therapy and norethindrone...She was initiated on rosuvastatin 40 mg daily, fenofibrate 145 mg daily, and prescription-strength omega-3 fatty acids, with plans for outpatient initiation of olezarsen. Extreme hypertriglyceridemia can present with a clinically mild and rapidly resolving course. This case emphasizes the disconnect between triglyceride levels and clinical severity and supports the effectiveness of conservative management with dietary modification and insulin therapy."

Case report • Clinical • Late-breaking abstract • CNS Disorders • Diabetes • Dyslipidemia • Fibromyalgia • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Musculoskeletal Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review. (PubMed, BJOG) - "Micronized progesterone shows additional benefits for sleep quality, while synthetic progestins such as medroxyprogesterone acetate, megestrol acetate, and norethindrone acetate variably confer bone protection. Its optimal use may be tailored to clinical context: micronized progesterone for sleep disturbance, norethindrone acetate for bone health, or progestins with known antineoplastic properties in hormone-sensitive tumours. Larger, high-quality studies are needed to better define long-term safety and efficacy."

Journal • Monotherapy • Review • Brain Cancer • Breast Cancer • Cardiovascular • CNS Disorders • Coronary Artery Disease • Endometrial Cancer • Endometriosis • Gynecologic Cancers • Gynecology • Hepatology • Meningioma • Oncology • Ovarian Cancer • Sarcoma • Sleep Disorder • Solid Tumor • Uterine Cancer • Venous Thromboembolism • Women's Health

Immediate volume reduction following transvaginal ultrasound-guided thermal ablation (interstitial myolysis) of a symptomatic uterine fibroid. (PubMed, Facts Views Vis Obgyn) - "Previous treatments, including levonorgestrel-releasing intrauterine system and oral therapy with relugolix, estradiol, and norethisterone had failed. Real-time ultrasound monitoring enables precise ablation and immediate confirmation of treatment efficacy. This video documents the immediate volumetric response of a uterine fibroid following transvaginal ultrasound-guided myolysis."

Journal • Anesthesia • Gynecology • Musculoskeletal Pain • Pain • Solid Tumor • Uterine Leiomyoma • Women's Health

Bioequivalence of a Fixed-Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open-Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions. (PubMed, Clin Pharmacol Drug Dev) - "The relugolix/estradiol/norethindrone acetate FDC demonstrated bioequivalence to the globally approved reference product (MYFEMBREE) with comparable tolerability. This provides a safe, effective, reversible non-surgical therapy for fibroid-related HMB, fulfilling an unmet need beyond surgery."

Clinical • Journal • Gynecologic Cancers • Gynecology • Hematological Disorders • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health

Polymenorrhea as an Unusual Presentation of Non-Classic Congenital Adrenal Hyperplasia (ENDO 2026) - "The patient was initiated on norethindrone therapy under obstetrics and gynecology guidance, resulting in symptomatic improvement, with coordinated endocrine follow-up for long-term monitoring... This case highlights an atypical presentation of non-classic congenital adrenal hyperplasia characterized by polymenorrhea and isolated elevation of 17-hydroxyprogesterone in the absence of clinical or biochemical hyperandrogenism. The mechanisms underlying polymenorrhea remain poorly understood, warranting further investigation to clarify its pathophysiology and to improve diagnostic recognition. The case also demonstrates that reliance on androgen excess alone may result in missed or delayed diagnosis."

Acne Vulgaris • Alopecia • Cardiovascular • Congenital Adrenal Hyperplasia • Endocrine Disorders • Gynecology • Hypertension • Immunology • Nephrology • Obesity • Obstetrics • Polyendocrine Metabolic Ovarian Syndrome

GnRH Analog followed by Sex Hormone Therapy as a Preventive Strategy against Ovarian Complications in Congenital Lipoid Adrenal Hyperplasia: A Case Report. (PubMed, Horm Res Paediatr) - "This is the first reported case of lipoid CAH managed with GnRH analog-mediated gonadotropin suppression followed by estrogen and progestin administration. Despite a large ovarian cyst and mildly elevated ovarian volume at baseline, both measures improved and were maintained within the normal range over eight years of follow-up. This approach may be useful not only for preventing ovarian complications but also for improving and sustaining normal ovarian morphology, and warrants further evaluation, although its long-term effects on bone health, uterine maturation, and fertility require careful assessment."

Journal • Cardiovascular • Endocrine Disorders • Heart Failure • Women's Health